Results 201 to 210 of about 23,451 (302)

Real‐world glycaemic outcomes observed with the use of Medtronic 780G, Tandem Control‐IQ and Omnipod 5 automated insulin delivery systems

open access: yesDiabetic Medicine, EarlyView.
Abstract Background No randomised controlled trials have directly compared commercially available hybrid automated insulin delivery (AID) systems, and real‐world comparative data remain limited. This study evaluated glycaemic outcomes across three hybrid AID systems in adults with type 1 diabetes (T1D).
Muhammad S. Khan   +10 more
wiley   +1 more source

Decision accuracy of simultaneously used real‐time CGM versus intermittently scanned CGM around exercise in type 1 diabetes: A secondary analysis of the ULTRAFLEXI‐1 study

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Continuous glucose monitoring (CGM) systems have become important technologies to improve glycaemia in people with type 1 diabetes (T1D). However, it has been shown that during rapid glucose change, sensor performance can deteriorate.
Sabrina Sanfilippo   +11 more
wiley   +1 more source

Exploring the gap between sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH): The voice of people living with diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Background and Aims In people with insulin‐treated diabetes experiencing hypoglycaemia, the multicentre Hypo‐METRICS study found that 60% of sensor‐detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person‐reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L).
Monika Cigler   +21 more
wiley   +1 more source

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley   +1 more source

Rethinking control‐IQ+ technology: Simple strategies for easy optimization

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy